MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, PHAT had -$14,413K decrease in cash & cash equivalents over the period. -$14,142K in free cash flow.

Cash Flow Overview

Change in Cash
-$14,413K
Free Cash flow
-$14,142K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-29,973 -170,126
Depreciation and amortization
156 349
Stock-based compensation
9,297 13,812
Issuance of pik interest debt
1,179 2,300
Accrued interest on revenue interest financing liability
4,799 15,491
Amortization of debt discount
775 1,430
Inventory reserve
0 819
Other
-1,209 -3,131
Prepaid expenses and other current assets
-1,392 -6,246
Accounts receivable, net
4,534 12,458
Accounts payable and accrued expenses
1,114 5,416
Accrued interest
10 43
Operating right-of-use assets and lease liabilities
66 66
Inventory
-395 14,178
Net cash used in operating activities
-14,115 -147,659
Cash paid for property and equipment
27 115
Net cash used in investing activities
-27 -115
Proceeds from issuance of common stock from exercise of stock options
293 80
Net proceeds from issuance of debt
0 0
Net proceeds from underwritten public offering
0 -
Payment of employee tax obligations related to vesting of performance stock units
-564 -
Net cash (used in) provided by financing activities
-271 80
Net decrease in cash and cash equivalents and restricted cash
-14,413 -147,694
Cash and cash equivalents at beginning of period
300,125 -
Cash and cash equivalents at end of period
138,018 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Phathom Pharmaceuticals, Inc. (PHAT)

Phathom Pharmaceuticals, Inc. (PHAT)